The Pennant Group (PNTG)
(Delayed Data from NSDQ)
$28.60 USD
+0.60 (2.14%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $28.59 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
The Pennant Group, Inc. (PNTG) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$26.75 | $28.00 | $25.00 | -4.46% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for The Pennant Group, Inc. comes to $26.75. The forecasts range from a low of $25.00 to a high of $28.00. The average price target represents a decline of 4.46% from the last closing price of $28.00.
Analyst Price Targets (4 )
Broker Rating
The Pennant Group, Inc. currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 25% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | Truist Securities | David S Macdonald | Hold | Hold |
7/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/7/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 4 |
Average Target Price | $26.75 |
LT Growth Rate | 13.00% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 69 of 253 |
Current Quarter EPS Est: | 0.21 |